HER2-Positive Breast Cancer: What It Means for Treatment
Written by North Editorial Staff | Clinically reviewed by Laura Morrissey, RN, BSN | Last reviewed: March 2026
Key Takeaways
HER2-positive breast cancer is defined by overexpression of the HER2 protein, which drives aggressive tumor growth. It accounts for approximately 15–20% of breast cancer diagnoses.
Before targeted HER2 therapy became available, HER2-positive breast cancer carried a worse prognosis than other subtypes. Today, it is one of the most treatable breast cancer subtypes, with excellent outcomes in early-stage disease.
The cornerstone of HER2-positive treatment is HER2-directed targeted therapy, which are drugs that specifically target the HER2 protein. Trastuzumab (Herceptin) was the first; a new generation of agents has followed.
Early-stage HER2-positive breast cancer is treated with curative intent. The majority of patients who receive standard HER2-directed therapy for early-stage disease achieve long-term remission or cure.
HER2-low is a newly defined category of breast cancers with low but detectable HER2 expression that were previously classified as HER2-negative. Newer agents are showing meaningful benefit in this group.
Brain metastases are more common in HER2-positive metastatic disease than in other subtypes, but newer agents, including tucatinib and trastuzumab deruxtecan, are specifically active in the brain.
What Is HER2-Positive Breast Cancer?
HER2 (human epidermal growth factor receptor 2) is a protein on the surface of cells that helps regulate normal cell growth. In HER2-positive breast cancer, amplification of the HER2 gene causes cells to produce far more HER2 receptors than normal. This overexpression acts like a constantly switched-on growth signal, causing cancer cells to grow and divide more rapidly.
HER2-positive breast cancer is defined as:
IHC 3+ (immunohistochemistry, 3+ on a 0–3 scale): Strong uniform HER2 protein overexpression visible on staining; typically considered HER2-positive without additional testing.
IHC 2+ with FISH amplification: Moderate HER2 protein staining that requires confirmation with fluorescence in situ hybridization (FISH), which directly detects amplification of the HER2 gene. FISH-positive in this context confirms HER2-positive status.
HER2 status is determined by pathology testing on tumor tissue obtained from biopsy. It is a required part of the initial breast cancer workup because it fundamentally changes treatment planning.
HER2-Positive vs. HER2-Low
Historically, breast cancers were classified as either HER2-positive (3+ or 2+/FISH+) or HER2-negative (0, 1+, or 2+/FISH-). Recent research has identified a clinically important subset within what was previously called “HER2-negative”:
HER2-low breast cancer is defined as IHC 1+ or IHC 2+ with negative FISH. According to published analyses, approximately 50–55% of breast cancers fall into the HER2-low category. These tumors were previously ineligible for HER2-directed therapy.
The importance of this distinction became clear with the DESTINY-Breast04 trial (published in 2022), which demonstrated that trastuzumab deruxtecan (T-DXd), a HER2-directed antibody-drug conjugate, significantly improved outcomes in patients with HER2-low metastatic breast cancer who had received prior chemotherapy. This trial effectively created a new treatment category and expanded the population eligible for HER2-directed therapy.
If your tumor was classified as HER2-negative under older testing paradigms, it is worth asking your oncologist whether your IHC score was 1+ or 2+/FISH-negative — if so, you may be HER2-low, which has treatment implications.
How HER2-Positive Breast Cancer Is Treated
Treatment for HER2-positive breast cancer is organized around the stage of disease.
Early-Stage HER2-Positive Breast Cancer
For early-stage disease (Stage I–III), treatment is given with curative intent and typically involves:
Neoadjuvant chemotherapy + dual HER2 blockade (for Stage II–III): Most patients with early-stage HER2-positive breast cancer now receive chemotherapy plus HER2-directed therapy before surgery. The current standard regimen includes:
Trastuzumab (Herceptin) + pertuzumab (Perjeta) — dual antibody HER2 blockade — given with chemotherapy (typically docetaxel + carboplatin, or an anthracycline-taxane sequence)
The goal of neoadjuvant treatment is to reduce tumor size before surgery, ideally achieving pathologic complete response (pCR) — no remaining cancer in the breast or lymph nodes at the time of surgery
Achieving pCR is a strong predictor of long-term outcomes. Patients who achieve pCR have excellent prognosis.
Post-surgery (adjuvant) treatment is determined by response to neoadjuvant therapy:
pCR achieved: Continue trastuzumab + pertuzumab to complete 1 year of HER2-directed therapy; add neratinib (extended adjuvant) for high-risk HR+ cases.
Residual disease at surgery: Switch to ado-trastuzumab emtansine (T-DM1/Kadcyla), an antibody-drug conjugate that delivers chemotherapy directly to HER2-expressing cells. The KATHERINE trial demonstrated T-DM1 significantly reduces recurrence risk in patients with residual disease after neoadjuvant therapy.
For patients with HR-positive disease, endocrine therapy (tamoxifen or aromatase inhibitor) is added as well.
Metastatic HER2-Positive Breast Cancer
For metastatic disease (Stage IV), treatment goals shift from cure to disease control and quality of life. The treatment landscape has evolved dramatically, and survival has improved substantially over the past decade.
First-line treatment: The current standard first-line regimen is trastuzumab + pertuzumab + taxane chemotherapy (the CLEOPATRA trial regimen). Median progression-free survival in this trial was approximately 18–20 months, with overall survival extending beyond 4 years in many patients.
Second-line treatment: Trastuzumab deruxtecan (T-DXd/Enhertu) is the current standard second-line choice after trastuzumab + pertuzumab, following the DESTINY-Breast03 trial, which demonstrated significantly superior outcomes compared with T-DM1.
Later-line options include: - Tucatinib (Tukysa) in combination with trastuzumab and capecitabine — particularly active in patients with brain metastases (HER2CLIMB trial) - T-DM1 (Kadcyla) - Lapatinib combinations - Neratinib with capecitabine - Margetuximab
HER2-Positive Breast Cancer and the Brain
Brain metastases occur in approximately 30–50% of patients with HER2-positive metastatic breast cancer over the course of their disease, compared with lower rates in other subtypes. This is thought to reflect both the biology of HER2-positive disease and the fact that large antibody-based drugs have limited ability to cross the blood-brain barrier.
Newer agents have specifically addressed this:
Tucatinib: A small-molecule HER2 tyrosine kinase inhibitor that crosses the blood-brain barrier. The HER2CLIMB trial demonstrated meaningful response rates in patients with active brain metastases.
Trastuzumab deruxtecan: Has also demonstrated intracranial activity, with the DESTINY-Breast12 trial showing responses in patients with brain metastases.
If you have HER2-positive metastatic breast cancer and develop neurological symptoms — headaches, vision changes, cognitive changes, new weakness — prompt imaging is essential, and your oncology team should be informed immediately.
Prognosis for HER2-Positive Breast Cancer
The transformation of HER2-positive breast cancer prognosis over the past two decades is one of oncology’s success stories:
Early-stage: 5-year relative survival rates are approximately 95–99% for Stage I–II disease. The majority of patients treated with current dual HER2-blockade regimens achieve long-term remission or cure.
Metastatic: Median overall survival has improved dramatically with newer agents. In the CLEOPATRA trial, median overall survival in the trastuzumab + pertuzumab arm exceeded 56 months, significantly longer than any prior treatment regimen for metastatic HER2-positive disease. With later-line therapies including T-DXd and tucatinib, many patients are living 5 years or more.
HER2-Positive Breast Cancer and Clinical Trials
Despite excellent outcomes with current therapies, significant research is underway to improve them further. Active trial areas include:
De-escalation trials: Studying whether some patients with small tumors can receive less intensive chemotherapy while maintaining outcomes
T-DXd in earlier settings: Testing whether moving T-DXd to first- or even neoadjuvant settings further improves outcomes
Novel bispecific antibodies engaging HER2 and immune cells simultaneously
Brain metastases-specific trials: Novel agents and combinations for intracranial disease
HER2-low settings: Expanding T-DXd and other agents to broader HER2-low populations
If you have HER2-positive or HER2-low breast cancer, clinical trials represent a path to treatments not yet widely available. Explore breast cancer clinical trials or start your search with North’s trial finder.
Frequently Asked Questions
Does HER2-positive mean a more aggressive cancer?
HER2-positive breast cancer does tend to grow faster than hormone receptor-positive, HER2-negative breast cancer. Before targeted HER2 therapy existed, it carried a significantly worse prognosis. However, with current HER2-directed therapies, outcomes for early-stage HER2-positive disease are excellent — comparable to or better than other subtypes — and outcomes for metastatic disease have improved dramatically.
What is the difference between HER2-positive and triple-negative breast cancer?
HER2-positive breast cancer overexpresses the HER2 protein and responds to HER2-directed targeted therapies. Triple-negative breast cancer (TNBC) is negative for estrogen receptors, progesterone receptors, AND HER2 — it has no targetable receptors under standard testing and historically has been treated with chemotherapy alone. Immunotherapy has changed outcomes for some TNBC patients, but TNBC remains a more challenging subtype than HER2-positive disease.
What is trastuzumab (Herceptin) and how does it work?
Trastuzumab is a monoclonal antibody that attaches to the HER2 receptor on cancer cell surfaces, blocking the growth signals the receptor sends. It also activates the immune system to attack HER2-expressing cancer cells. It was the first HER2-directed therapy approved and remains a cornerstone of HER2-positive treatment. It is given intravenously every 3 weeks, often in combination with pertuzumab and/or chemotherapy.
What is trastuzumab deruxtecan (T-DXd)?
Trastuzumab deruxtecan (brand name: Enhertu) is an antibody-drug conjugate (ADC) — a HER2-directed antibody linked to a chemotherapy payload. The antibody carries the chemotherapy directly to HER2-expressing cancer cells, releasing it upon internalization. T-DXd has shown remarkable efficacy in HER2-positive metastatic breast cancer and, notably, in HER2-low disease — where it has created an entirely new treatment category.
Can HER2-positive breast cancer come back after treatment?
Yes, recurrence is possible, though the risk is substantially reduced with current treatment regimens. Risk of recurrence is highest in the first 5 years after diagnosis, particularly for higher-stage disease. Hormone receptor-positive HER2-positive cancer (sometimes called “triple-positive”) can also recur late — sometimes more than 10 years after initial treatment — which is why extended endocrine therapy is recommended for HR+ disease. Your oncology team will establish a surveillance plan based on your specific stage and treatment.
References
National Cancer Institute. (2024). Breast Cancer Treatment — Health Professional Version. https://www.cancer.gov/types/breast/hp/breast-treatment-pdq
Swain, S. M., et al. (2020). Pertuzumab, Trastuzumab, and Docetaxel for HER2-Positive Metastatic Breast Cancer (CLEOPATRA): 8-year follow-up of a double-blind, randomised, placebo-controlled, phase 3 study. The Lancet Oncology. https://pubmed.ncbi.nlm.nih.gov/32171426/
von Minckwitz, G., et al. (2019). Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer (KATHERINE). New England Journal of Medicine. https://www.nejm.org/doi/10.1056/NEJMoa1814017
Cortés, J., et al. (2022). Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer (DESTINY-Breast03). New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa2115022
Modi, S., et al. (2022). Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer (DESTINY-Breast04). New England Journal of Medicine. https://www.nejm.org/doi/10.1056/NEJMoa2203690
Murthy, R. K., et al. (2020). Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer (HER2CLIMB). New England Journal of Medicine. https://www.nejm.org/doi/10.1056/NEJMoa1914609